07:31 AM EDT, 07/23/2025 (MT Newswires) -- Castle Biosciences ( CSTL ) said Wednesday the US Food and Drug Administration has granted breakthrough device designation for the company's DecisionDx-Melanoma test.

DecisionDx-Melanoma is a gene expression profile test that provides results to guide risk-aligned management decisions for patients diagnosed with stage I to III cutaneous melanoma, a type of skin cancer.

According to the company, the FDA grants breakthrough device designation to qualifying devices that may offer improved treatment or diagnosis of life-threatening or irreversibly debilitating diseases when compared with currently available alternatives.

Shares of Castle Biosciences ( CSTL ) rose more than 7% in pre-bell Wednesday.

Price: 17.50, Change: +1.18, Percent Change: +7.23